| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36,7 k € | -55.6% | 82,6 k € | 0.0% | 82,6 k € | +19.1% | 69,4 k € | -15.0% | 81,6 k € | -33.3% | 122,4 k € | -4.1% | 127,7 k € | 0.0% | 127,7 k € | +4.3% | 122,4 k € | 0.0% | 122,4 k € | 0.0% | 122,4 k € | |
| Gross margin | 26,3 k € | -63.2% | 71,6 k € | +2.4% | 69,9 k € | +13.4% | 61,6 k € | -16.5% | 73,8 k € | -29.5% | 104,8 k € | -9.0% | 115,1 k € | +4.8% | 109,8 k € | -3.1% | 113,3 k € | -3.6% | 117,5 k € | -2.6% | 120,6 k € | |
| EBITDA | 25,9 k € | -63.6% | 71,2 k € | +2.4% | 69,5 k € | +13.5% | 61,3 k € | -14.3% | 71,5 k € | -31.5% | 104,4 k € | -8.0% | 113,4 k € | +4.2% | 108,9 k € | -3.5% | 112,9 k € | -3.7% | 117,2 k € | -2.6% | 120,3 k € | |
| Operating profit | 25,9 k € | +207.4% | -24,1 k € | +7.3% | -26,0 k € | +23.5% | -34,0 k € | -42.9% | -23,8 k € | -362.0% | 9,1 k € | -49.2% | 17,9 k € | +33.9% | 13,4 k € | -22.9% | 17,3 k € | -19.8% | 21,6 k € | -12.3% | 24,7 k € | |
| Profit/loss | 25,9 k € | +207.2% | -24,2 k € | +9.0% | -26,5 k € | +25.9% | -35,8 k € | -9.7% | -32,7 k € | -1572.9% | -2,0 k € | -129.8% | 6,6 k € | +286.9% | 1,7 k € | -52.5% | 3,6 k € | -23.2% | 4,6 k € | +2091.5% | 212,0 € | |
| Equity | -72,4 k € | +26.3% | -98,3 k € | -32.6% | -74,1 k € | -55.8% | -47,6 k € | -305.0% | -11,8 k € | -156.2% | 20,9 k € | -8.5% | 22,9 k € | +40.2% | 16,3 k € | +11.6% | 14,6 k € | +32.2% | 11,1 k € | +72.4% | 6,4 k € | |
| Total assets | 273,1 k € | -6.2% | 291,2 k € | -19.2% | 360,4 k € | -14.6% | 422,2 k € | -16.3% | 504,6 k € | -15.7% | 598,5 k € | +22.5% | 488,7 k € | -15.5% | 578,6 k € | -15.0% | 681,0 k € | -30.9% | 985,5 k € | -8.6% | 1,1 M € | |
| Cash | 293,0 € | +2830.0% | 10,0 € | -88.9% | 90,0 € | — | 171,0 € | -27.2% | 235,0 € | +410.9% | 46,0 € | -95.0% | 918,0 € | +2.7% | 894,0 € | +22.8% | 728,0 € | +116.0% | 337,0 € | |||
| Debts | 345,5 k € | -11.3% | 389,5 k € | -10.4% | 434,5 k € | -7.5% | 469,8 k € | -9.0% | 516,3 k € | -10.6% | 577,6 k € | +24.0% | 465,8 k € | -17.2% | 562,3 k € | -15.6% | 666,4 k € | -31.6% | 974,4 k € | -9.0% | 1,1 M € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+2830.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Beisol Pharma Merkplas is a Private company with limited liability incorporated in 2014. Its main activity is: Location-bail de propriété intellectuelle et de produits similaires, à l’exception des œuvres soumises à copyright. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.